News
Dr. Reddy's Laboratories Q3 PAT may dip 2% YoY to Rs. 781.6 cr: Prabhudas Lilladher

Dr Reddy's Labs | Company and Russian Direct Investment Fund (RDIF) commenced clinical trials for Sputnik V vaccine in India. (Image: drreddys.com)

Trade
• Watchlist
• Portfolio
• Message
• Set Alert

live

• bselive
• nselive

Volume Todays L/H

More

×

Prabhudas Lilladher has come out with its third quarter (October-December' 20) earnings estimates for the Pharma sector. The brokerage house expects Dr. Reddy's Laboratories to report net profit at Rs. 781.6 crore down 2% year-on-year (down 9.9% quarter-on-quarter).

Net Sales are expected to increase by 12.3 percent Y-o-Y (up 0.5 percent Q-o-Q) to Rs. 4,397.1 crore, according to Prabhudas Lilladher.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 21.5 percent Y-o-Y (up 1.5 percent Q-o-Q) to Rs. 1,031.3 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.